Regeneron’s Antibody Gets Updated FDA Nod
- ByTipRanks-
Regeneron Pharmaceuticals’ (NASDAQ: REGN) investigational COVID-19 antibody cocktail, REGEN-COV (casirivimab and imdevimab), has received updated authorization for emergency use...
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Regeneron Pharmaceuticals Inc (REGN)
577.13
+2.52(+0.44%)
After Hours
577.13
0.00(0.00%)
- Real-time Data
- Volume:362,192
- Bid/Ask:570.30/585.15
- Day's Range:570.38 - 580.87
REGN Overview
- Prev. Close
- 577.13
- Day's Range
- 570.38-580.87
- Revenue
- 9.2B
- Open
- 577.12
- 52 wk Range
- 441.3-657.24
- EPS
- 35.35
- Volume
- 362,192
- Market Cap
- 59.77B
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 737,567
- P/E Ratio
- 16.33
- Beta
- 0.13
- 1-Year Change
- -8.69%
- Shares Outstanding
- 103,556,326
- Next Earnings Date
- 04 Aug 2021
What is your sentiment on Regeneron Pharmaceuticals Inc?
or
Market is currently closed. Voting is open during market hours.
Regeneron Pharmaceuticals Inc News
- FDA Approves Regeneron - Roche's COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
- ByBenzinga-
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the investigational COVID-19 antibody...
- Regeneron wins expanded authorization from FDA for COVID-19 antibody cocktail
- BySeeking Alpha-
Regeneron Pharmaceuticals announced that the FDA has updated the Emergency Use Authorization ((EUA)) for its COVID-19 antibody cocktail REGEN-COV (casirivimab and...
Regeneron Pharmaceuticals Inc Analysis
- Regeneron: Rapid Growth Seems To Be On A Pause
- BySeeking Alpha-
- Regeneron: Only 1 Year Of High Growth Left
- BySeeking Alpha-
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Neutral | Sell | Buy | Strong Buy |
| Technical Indicators | Strong Buy | Sell | Sell | Sell | Strong Buy |
| Summary | Strong Buy | Neutral | Sell | Neutral | Strong Buy |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 306.00 | 305.95 | 295.76 | +16.25 | +5.61% | 3.93M | London | |||
| 46.92 | 46.92 | 46.35 | +0.69 | +1.48% | 31.55M | London | |||
| 691.51 | 752.50 | 687.00 | -38.50 | -5.25% | 1.28M | London | |||
| 1,442.00 | 1,505.26 | 1,419.57 | -130.00 | -8.27% | 262.12K | London | |||
| 503.80 | 508.60 | 503.00 | -5.20 | -1.02% | 354.48K | London | |||
| 1,427.00 | 1,437.50 | 1,423.00 | -12.00 | -0.83% | 1.00M | London | |||
| 0.149 | 0.00 | 0.00 | 0.0000 | 0.00% | 0.00 | London | |||
| 2,350.50 | 2,358.50 | 2,321.50 | +1.50 | +0.06% | 648.68K | London | |||
| 1,851.20 | 1,874.00 | 1,850.75 | -16.80 | -0.90% | 10.87K | London | |||
| 16.40 | 16.84 | 15.98 | +0.85 | +5.47% | 595.19K | London | |||
| 1,690.50 | 1,731.00 | 1,689.00 | -41.50 | -2.40% | 228.00K | London | |||
| 171.57 | 175.93 | 170.52 | -1.89 | -1.09% | 5.45M | London | |||
| 2,705.40 | 2,862.20 | 2,696.80 | -98.6 | -3.52% | 59.56K | London | |||
| 8.80 | 8.95 | 8.54 | -0.11 | -1.23% | 595.70K | London | |||
| 117.16 | 117.73 | 116.59 | +0.36 | +0.31% | 1.95M | London |
Regeneron Pharmaceuticals Inc Company Profile
Regeneron Pharmaceuticals Inc Company Profile
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion. As of December 31, 2016, the Company had 16 product candidates in clinical development, which consisted of a Trap-based clinical program and 15 fully human monoclonal antibody product candidates.
Read More
- 2021-03-23 19:40:42
this is the worst stock I had ever invested in. it just keeps going down and down with no bottom in sight. what a disgrace.- 2021-04-07 01:04:40
Me too
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.